FRANKLIN LAKES, N.J.
Nov. 1, 2012
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the completion of the sale of its BD Biosciences - Discovery Labware unit, excluding its Advanced Bioprocessing platform, to Corning Incorporated (NYSE:GLW), the world leader in specialty glass and ceramics. On
April 9, 2012
, BD announced that it had signed an agreement to sell these assets to Corning.
The Company expects to record a gain within discontinued operations in the first quarter of fiscal year 2013.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in
Franklin Lakes, New Jersey
, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit
Colleen T. White
, Corporate Communications – 201-847-5369
Monique N. Dolecki
, Investor Relations – 201-847-5378
SOURCE BD (Becton, Dickinson and Company)